Biosceptre

Biosceptre is a UK-based biotechnology company leveraging its proprietary target nfP2X7 to develop next-generation cancer therapies. Biosceptre has an experienced team of scientists and management, located in advanced facilities at the Babraham Research Campus in Cambridge, UK, and in Sydney, Australia. Biosceptre has multiple clinical programs aimed at utilizing nfP2X7 through a range of approaches, including systemic antibodies, vaccines, and localized treatments. A comprehensive global intellectual property portfolio extensively covers the target itself and various drug modalities, as well as multiple candidates designed to harness nfP2X7.